Matt Hewitt
Stock Analyst at Craig-Hallum
(2.69)
# 1,931
Out of 5,120 analysts
43
Total ratings
54.05%
Success rate
4.13%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $16.77 | +114.67% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $7.13 | +68.26% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.20 | +172.73% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $22.33 | +43.30% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $48.70 | +31.42% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $197.93 | -29.27% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.51 | +1,877.46% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $14.09 | +112.92% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $0.87 | +705.43% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $151.12 | +32.35% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.79 | +458.66% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $5.37 | +458.66% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.34 | +117,202.05% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $16.77
Upside: +114.67%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $7.13
Upside: +68.26%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.20
Upside: +172.73%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $22.33
Upside: +43.30%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $48.70
Upside: +31.42%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $197.93
Upside: -29.27%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.51
Upside: +1,877.46%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $14.09
Upside: +112.92%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $0.87
Upside: +705.43%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $151.12
Upside: +32.35%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.79
Upside: +458.66%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $5.37
Upside: +458.66%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.34
Upside: +117,202.05%